FB 1005
Alternative Names: FB-1005Latest Information Update: 12 Jul 2022
At a glance
- Originator 4B Technologies
- Class Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Oedema; Stroke
Most Recent Events
- 12 Jul 2022 Early research in Oedema in China (unspecified route)
- 01 Oct 2021 Early research in Stroke in China (unspecified route) (4B Technologies pipeline, October 2021)